{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:06:03Z","timestamp":1790229963656,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While monoclonal antibodies (mAbs) targeting the CGRP pathway have revolutionized migraine management due to their improved tolerance and adherence, concerns remain about their potential impact on blood pressure (BP), especially in older patients, due to CGRP-mediated vasodilation blockade. Given the growing use of these therapies in older populations, assessing their cardiovascular (CV) safety is of paramount importance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicentric observational prospective study focused on migraine sufferers aged\u2009\u2265\u200960 who began erenumab, galcanezumab, or fremanezumab for prevention. Baseline, three-month, and twelve-month BP measurements were collected. Changes in antihypertensive medication and \"Newly or Worsened Hypertensive\" patients (NWHP) were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 155 patients receiving anti-CGRP mAbs (40 Erenumab, 47 Galcanezumab, 68 Fremanezumab), 42.5% had hypertension history and 39% were on antihypertensive treatment. No significant systolic or diastolic BP changes occurred at any time point compared to baseline (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05), with no differences between the three groups. After one year, 20\/155 (12.9%) patients were considered NWHP; 11\/20 had prior hypertension, and 5\/11 adjusted antihypertensive therapy. Among 9\/20 newly hypertensive patients, 5\/9 had a single measurement above the normal threshold with no requirement for new pharmacological therapy. A higher baseline BP value was associated with increased BP (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The study concludes that treatment with anti-CGRP mAbs over one year does not significantly affect BP in patients aged\u2009\u2265\u200960, nor does it increase the incidence of hypertension compared to general population trends. Nonetheless, continuous monitoring and further long-term studies are necessary to fullya scertain the cardiovascular safety of these medications in the elderly.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10072-024-07567-9","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T09:01:57Z","timestamp":1716627717000},"page":"5365-5373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Blood pressure monitoring in elderly migraineurs starting an anti-CGRP monoclonal antibody: a real-world prospective study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9265-3281","authenticated-orcid":false,"given":"Davide","family":"Mascarella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Andrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8432-1888","authenticated-orcid":false,"given":"Carlo","family":"Baraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5934-5535","authenticated-orcid":false,"given":"Claudia","family":"Altamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-2438","authenticated-orcid":false,"given":"Valentina","family":"Favoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8572-3421","authenticated-orcid":false,"given":"Flavia","family":"Lo Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pierangeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9594-9336","authenticated-orcid":false,"given":"Fabrizio","family":"Vernieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Guerzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4668-4295","authenticated-orcid":false,"given":"Sabina","family":"Cevoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"key":"7567_CR1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","volume":"16","author":"VL Feigin","year":"2017","unstructured":"Feigin VL, Abajobir AA, Abate KH, Abd-Allah F, Abdulle AM, Abera SF et al (2017) Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet Neurol 16:877\u2013897. https:\/\/doi.org\/10.1016\/S1474-4422(17)30299-5","journal-title":"The Lancet Neurol"},{"key":"7567_CR2","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/03331024211014616","volume":"41","author":"AR Gantenbein","year":"2021","unstructured":"Gantenbein AR, Agosti R, Gobbi C, Fl\u00fcgel D, Schankin CJ, Viceic D et al (2021) Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment \u2013 a real-life cohort study. Cephalalgia 41:1181\u20131186. https:\/\/doi.org\/10.1177\/03331024211014616","journal-title":"Cephalalgia"},{"key":"7567_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"on behalf of Lifting The Burden: the Global Campaign against Headache, Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z (2020) Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21:137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0. (s10194-020-01208\u20130)","journal-title":"J Headache Pain"},{"key":"7567_CR4","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s11886-014-0524-1","volume":"16","author":"S Sacco","year":"2014","unstructured":"Sacco S, Kurth T (2014) Migraine and the risk for stroke and cardiovascular disease. Curr Cardiol Rep 16:524. https:\/\/doi.org\/10.1007\/s11886-014-0524-1","journal-title":"Curr Cardiol Rep"},{"key":"7567_CR5","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1212\/WNL.0b013e3181d0cc8b","volume":"74","author":"ME Bigal","year":"2010","unstructured":"Bigal ME, Kurth T, Santanello N, Buse D, Golden W, Robbins M et al (2010) Migraine and cardiovascular disease: a population-based study. Neurology 74:628\u2013635. https:\/\/doi.org\/10.1212\/WNL.0b013e3181d0cc8b","journal-title":"Neurology"},{"key":"7567_CR6","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.amjmed.2009.12.021","volume":"123","author":"JT Spector","year":"2010","unstructured":"Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S (2010) Migraine Headache and Ischemic Stroke Risk: an Updated Meta-analysis. Am J Med 123:612\u2013624. https:\/\/doi.org\/10.1016\/j.amjmed.2009.12.021","journal-title":"Am J Med"},{"key":"7567_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1468-2982.2009.01904.x","volume":"30","author":"M Kruit","year":"2010","unstructured":"Kruit M, van Buchem M, Launer L, Terwindt G, Ferrari M (2010) Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA study. Cephalalgia 30:129\u2013136. https:\/\/doi.org\/10.1111\/j.1468-2982.2009.01904.x","journal-title":"Cephalalgia"},{"key":"7567_CR8","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1177\/03331024211020398","volume":"41","author":"K Manandhar","year":"2021","unstructured":"Manandhar K, Risal A, Koju R, Linde M, Steiner TJ (2021) If headache has any association with hypertension, it is negative. Evidence from a population-based study in Nepal. Cephalalgia 41:1310\u20137. https:\/\/doi.org\/10.1177\/03331024211020398","journal-title":"Cephalalgia"},{"key":"7567_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/bmj.318.7175.13","volume":"318","author":"CL Chang","year":"1999","unstructured":"Chang CL, Donaghy M, Poulter N (1999) Migraine and stroke in young women: case-control study. BMJ 318:13\u201318. https:\/\/doi.org\/10.1136\/bmj.318.7175.13","journal-title":"BMJ"},{"key":"7567_CR10","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1212\/01.WNL.0000158326.31368.04","volume":"64","author":"PE Stang","year":"2005","unstructured":"Stang PE, Carson AP, Rose KM, Mo J, Ephross SA, Shahar E et al (2005) Headache, cerebrovascular symptoms, and stroke: the atherosclerosis risk in communities study. Neurology 64:1573\u20131577. https:\/\/doi.org\/10.1212\/01.WNL.0000158326.31368.04","journal-title":"Neurology"},{"key":"7567_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1046\/j.1526-4610.1999.3906409.x","volume":"39","author":"M Cirillo","year":"1999","unstructured":"Cirillo M, Stellato D, Lombardi C, Santo NG, Covelli V (1999) Headache and cardiovascular risk factors: positive association with hypertension. Headache 39:409\u2013416. https:\/\/doi.org\/10.1046\/j.1526-4610.1999.3906409.x","journal-title":"Headache"},{"key":"7567_CR12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.tips.2016.06.002","volume":"37","author":"A MaassenVanDenBrink","year":"2016","unstructured":"MaassenVanDenBrink A, Meijer J, Villal\u00f3n CM, Ferrari MD (2016) Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci 37:779\u2013788. https:\/\/doi.org\/10.1016\/j.tips.2016.06.002","journal-title":"Trends Pharmacol Sci"},{"key":"7567_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s10194-019-0979-y","volume":"20","author":"V Favoni","year":"2019","unstructured":"European Headache Federation School of Advanced Studies (EHF-SAS), Favoni V, Giani L, Al-Hassany L, Asioli GM, Butera C et al (2019) CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? J Headache Pain 20:27. https:\/\/doi.org\/10.1186\/s10194-019-0979-y","journal-title":"J Headache Pain"},{"key":"7567_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0304-3940(85)90166-1","volume":"58","author":"L Edvinsson","year":"1985","unstructured":"Edvinsson L, Fredholm BB, Hamel E, Jansen I, Verrecchia C (1985) Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neurosci Lett 58:213\u2013217. https:\/\/doi.org\/10.1016\/0304-3940(85)90166-1","journal-title":"Neurosci Lett"},{"key":"7567_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-017-0768-4","volume":"18","author":"A Erdling","year":"2017","unstructured":"Erdling A, Sheykhzade M, Edvinsson L (2017) Differential inhibitory response to telcagepant on \u03b1CGRP induced vasorelaxation and intracellular Ca2+ levels in the perfused and non-perfused isolated rat middle cerebral artery. J Headache Pain 18:61. https:\/\/doi.org\/10.1186\/s10194-017-0768-4","journal-title":"J Headache Pain"},{"key":"7567_CR16","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/HYPERTENSIONAHA.113.02517","volume":"63","author":"S-J Smillie","year":"2014","unstructured":"Smillie S-J, King R, Kodji X, Outzen E, Pozsgai G, Fernandes E et al (2014) An ongoing role of \u03b1-calcitonin gene-related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. Hypertension 63:1056\u20131062. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.02517","journal-title":"Hypertension"},{"key":"7567_CR17","doi-asserted-by":"publisher","first-page":"5731","DOI":"10.1073\/pnas.83.15.5731","volume":"83","author":"J McCulloch","year":"1986","unstructured":"McCulloch J, Uddman R, Kingman TA, Edvinsson L (1986) Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci USA 83:5731\u20135735. https:\/\/doi.org\/10.1073\/pnas.83.15.5731","journal-title":"Proc Natl Acad Sci USA"},{"key":"7567_CR18","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V et al (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38:1026\u20131037. https:\/\/doi.org\/10.1177\/0333102418759786","journal-title":"Cephalalgia"},{"key":"7567_CR19","doi-asserted-by":"publisher","first-page":"e2724","DOI":"10.1212\/WNL.0000000000012029","volume":"96","author":"PJ Goadsby","year":"2021","unstructured":"Goadsby PJ, Reuter U, Lanteri-Minet M, da Silva Lima GP, Hours-Zesiger P, Fernandes C et al (2021) Long-term efficacy and safety of erenumab: results from 64 weeks of the LIBERTY study. Neurology 96:e2724-35. https:\/\/doi.org\/10.1212\/WNL.0000000000012029","journal-title":"Neurology"},{"key":"7567_CR20","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1212\/WNL.0000000000010019","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F et al (2020) One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study. Neurology 95:e469\u2013e479. https:\/\/doi.org\/10.1212\/WNL.0000000000010019","journal-title":"Neurology"},{"key":"7567_CR21","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91:e2211\u2013e2221. https:\/\/doi.org\/10.1212\/WNL.0000000000006640","journal-title":"Neurology"},{"key":"7567_CR22","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1177\/0333102420905321","volume":"40","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Goadsby PJ, Lucas C, Jensen R, Bardos JN, Martinez JM et al (2020) Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment. Cephalalgia 40:935\u2013948. https:\/\/doi.org\/10.1177\/0333102420905321","journal-title":"Cephalalgia"},{"key":"7567_CR23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/head.14032","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B et al (2021) Erenumab in the prevention of high\u2010frequency episodic and chronic migraine: erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real\u2010life study. Headache: J Head Face Pain 61:363\u201372. https:\/\/doi.org\/10.1111\/head.14032","journal-title":"Headache: J Head Face Pain"},{"key":"7567_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","volume":"22","author":"F Vernieri","year":"2021","unstructured":"for the GARLIT Study Group, Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C et al (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22:35. https:\/\/doi.org\/10.1186\/s10194-021-01247-1","journal-title":"J Headache Pain"},{"key":"7567_CR25","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319:1999. https:\/\/doi.org\/10.1001\/jama.2018.4853","journal-title":"JAMA"},{"key":"7567_CR26","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet 394:1030\u20131040. https:\/\/doi.org\/10.1016\/S0140-6736(19)31946-4","journal-title":"The Lancet"},{"key":"7567_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s10194-022-01396-x","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C, d\u2019Onofrio F, Albanese M, Cetta I et al (2022) Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain 23:46. https:\/\/doi.org\/10.1186\/s10194-022-01396-x","journal-title":"J Headache Pain"},{"key":"7567_CR28","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1111\/head.14208","volume":"61","author":"DW Dodick","year":"2021","unstructured":"Dodick DW, Tepper SJ, Ailani J, Pannacciulli N, Navetta MS, Loop B et al (2021) Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data. Headache 61:1411\u20131420. https:\/\/doi.org\/10.1111\/head.14208","journal-title":"Headache"},{"key":"7567_CR29","doi-asserted-by":"publisher","unstructured":"de Vries Lentsch S, Heleen van der Arend BW, Maassen van den Brink A, Terwindt GM (2022) Blood pressure in migraine patients treated with monoclonal anti-CGRP (receptor) antibodies: a prospective follow-up study. Neurology https:\/\/doi.org\/10.1212\/WNL.0000000000201008","DOI":"10.1212\/WNL.0000000000201008"},{"key":"7567_CR30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/head.14051","volume":"61","author":"S Saely","year":"2021","unstructured":"Saely S, Croteau D, Jawidzik L, Brinker A, Kortepeter C (2021) Hypertension: A new safety risk for patients treated with erenumab. Headache 61:202\u2013208. https:\/\/doi.org\/10.1111\/head.14051","journal-title":"Headache"},{"key":"7567_CR31","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1212\/WNL.0000000000008743","volume":"94","author":"D Kudrow","year":"2020","unstructured":"Kudrow D, Pascual J, Winner PK, Dodick DW, Tepper SJ, Reuter U et al (2020) Vascular safety of erenumab for migraine prevention. Neurology 94:e497-510. https:\/\/doi.org\/10.1212\/WNL.0000000000008743","journal-title":"Neurology"},{"key":"7567_CR32","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R et al (2020) Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology 95:e2487\u2013e2499. https:\/\/doi.org\/10.1212\/WNL.0000000000010600","journal-title":"Neurology"},{"key":"7567_CR33","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim B-K, L\u00e1inez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet Neurol 19:814\u2013825. https:\/\/doi.org\/10.1016\/S1474-4422(20)30279-9","journal-title":"The Lancet Neurol"},{"key":"7567_CR34","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s10072-021-05426-5","volume":"43","author":"U Pensato","year":"2022","unstructured":"Pensato U, Baraldi C, Favoni V, Cainazzo MM, Torelli P, Querzani P et al (2022) Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Neurol Sci 43:1273\u20131280. https:\/\/doi.org\/10.1007\/s10072-021-05426-5","journal-title":"Neurol Sci"},{"key":"7567_CR35","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/ana.25831","volume":"88","author":"IA Mulder","year":"2020","unstructured":"Mulder IA, Li M, Vries T, Qin T, Yanagisawa T, Sugimoto K et al (2020) Anti-migraine calcitonin gene-related peptide receptor antagonists worsen cerebral ischemic outcome in mice. Ann Neurol 88:771\u2013784. https:\/\/doi.org\/10.1002\/ana.25831","journal-title":"Ann Neurol"},{"key":"7567_CR36","doi-asserted-by":"publisher","unstructured":"Bahr-Hosseini M, Mei\u00dfner N, Reidler P, Saver JL, Tiedt S (2023) Plasma CGRP levels are not associated with collateral flow and outcome after stroke. Stroke 54. https:\/\/doi.org\/10.1161\/STROKEAHA.123.042580","DOI":"10.1161\/STROKEAHA.123.042580"},{"key":"7567_CR37","doi-asserted-by":"publisher","first-page":"676","DOI":"10.2105\/AJPH.78.6.676","volume":"78","author":"AL Dannenberg","year":"1988","unstructured":"Dannenberg AL, Garrison RJ, Kannel WB (1988) Incidence of hypertension in the framingham study. Am J Public Health 78:676\u2013679. https:\/\/doi.org\/10.2105\/AJPH.78.6.676","journal-title":"Am J Public Health"},{"key":"7567_CR38","doi-asserted-by":"publisher","first-page":"e952","DOI":"10.1097\/MD.0000000000000952","volume":"94","author":"ME Lacruz","year":"2015","unstructured":"Lacruz ME, Kluttig A, Hartwig S, L\u00f6er M, Tiller D, Greiser KH et al (2015) Prevalence and incidence of hypertension in the general adult population: results of the CARLA-cohort study. Medicine 94:e952. https:\/\/doi.org\/10.1097\/MD.0000000000000952","journal-title":"Medicine"},{"key":"7567_CR39","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s10194-023-01640-y","volume":"24","author":"K Wang","year":"2023","unstructured":"Wang K, Fenton BT, Dao VX, Guirguis AB, Anthony SE, Skanderson M et al (2023) Trajectory of blood pressure after initiating anti-calcitonin gene-related peptide treatment of migraine: a target trial emulation from the veterans health administration. J Headache Pain 24:108. https:\/\/doi.org\/10.1186\/s10194-023-01640-y","journal-title":"J Headache Pain"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07567-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07567-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07567-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:04:02Z","timestamp":1728691442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07567-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["7567"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07567-9","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,25]]},"assertion":[{"value":"29 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by an independent ethics committee or local institutional review board at each participating site (protocol numbers: 20073, 50\/2020\/OSS\/AOUMO and 625\/2020\/OSS\/AUMO, and 30\/20 OSS ComEt CBM, for the three participant centres). Written informed consent was obtained from all enrolled patients, both for study participation and data publication. All procedures were conducted according to the latest version of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Standard protocol approvals, registrations, and patient consents"}},{"value":"D. M. received travel grants from Ely Lilly; G.A.has no disclosure; C. A. received travel grants and honoraria from Novartis, Eli Lilly, Allergan, Lusofarmaco, and Laborest; S.C. and G.P. received travel grants, honoraria for advisory boards, speaker panels or clinical investigation studies from Novartis, Teva, Lilly, Allergan, Ibsa, andL undbeck; F.V. received travel grants, honoraria for advisory boards, and speaker panels from Allergan, Angelini, Lilly, Lundbeck, Novartis, and Teva; C.B. and S.G. received travel grants and honorary from Allergan, Novartis, Teva and ElyLilly; F.L. received travel grants and honoraria from Allergan\/Abbvie, Eli Lilly.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}